Oxford Biodynamics — Operational Update

Oxford BioDynamics posts 124% test sales growth, boosted by £9.15m equity raise.

What the company is saying

Oxford BioDynamics highlights a 124% year-on-year increase in EpiSwitch PSE test sales, reaching approximately 4,200 units for FY26. The company frames this as a key driver for revenue growth from £1.10m in FY25 to £1.65m in FY26. Management emphasizes operational momentum with a record of over 500 tests sold in September 2026 and claims the current sales run-rate is more than double last year's. The announcement spotlights commercial progress, notably the first pharma Orion agreement with Johnson & Johnson and the launch of an Orion early-access programme, though no quantitative details are provided for these initiatives. The company also points to a US reorganisation and cost reductions, stating these are intended to improve throughput and reimbursement, but does not quantify their impact. Liquidity is underscored by a £9.15m equity raise in August 2026 and £7.4m in cash at period end, with an additional £0.5m received post-period.

What the data suggests

The company delivered FY26 revenue of £1.65m, up from £1.10m in FY25, reflecting a 50% increase. Test sales surged 124% year-on-year to approximately 4,200, with a new monthly record of over 500 tests in September 2026. The current sales run-rate is described as more than double the prior year, but no exact monthly or quarterly figures are disclosed to verify this. Cash and cash equivalents were £7.4m at 30 September 2026, following a substantial £9.15m equity raise in August and an additional £0.5m post-period, indicating strong liquidity. While the company references commercial progress with Johnson & Johnson and an Orion early-access programme, no contractual values, participant numbers, or revenue contributions from these are disclosed. Operational improvements in the US are cited as intended to enhance throughput and reimbursement, but there are no figures for cost savings or margin impact. The data demonstrates accelerating sales and a strengthened balance sheet, but lacks detail on profitability, margins, or the financial impact of strategic initiatives.

Analysis

The announcement presents a positive tone, highlighting strong year-on-year revenue and test sales growth, a robust cash position, and successful capital raising. These realised metrics are well-supported by disclosed figures. However, the narrative inflates the signal by emphasizing commercial progress (e.g., the Johnson & Johnson agreement and Orion early-access programme) without providing quantitative details or contractual specifics. The claim that US reorganisation and cost reductions will improve throughput and reimbursement is forward-looking and lacks measurable outcomes. The large equity raise signals significant capital intensity, but there is no immediate evidence of profitability or cost savings, and no profit or margin metrics are disclosed. The gap between narrative and evidence is moderate: operational growth is real, but the impact of strategic initiatives and capital deployment remains unquantified.

Risk flags

• ●The announcement does not disclose profitability, margin, or cost-saving figures, making it unclear whether revenue growth is translating into sustainable earnings. This limits visibility into the company's path to profitability and the effectiveness of recent operational changes.
• ●While commercial agreements with Johnson & Johnson and the Orion early-access programme are highlighted, the absence of quantitative details or contractual terms means their financial impact is unverified. This raises the risk that headline partnerships may not deliver material revenue or margin improvements.
• ●The company relies on continued sales growth and successful commercialisation of its EpiSwitch PSE tests, but the lack of specific forward sales guidance or customer concentration data introduces uncertainty about the durability of current momentum.

Bottom line

Oxford BioDynamics reports strong operational progress, with 124% year-on-year test sales growth and a 50% revenue increase to £1.65m for FY26. The £9.15m equity raise and £7.4m cash position provide a solid liquidity buffer for near-term operations. However, the announcement does not quantify profitability, margins, or the financial impact of new commercial agreements, leaving the sustainability of growth and the path to earnings unclear. Investors should focus on whether future updates provide detail on contract values, cost savings, and margin improvement. The most important takeaway is that while operational momentum is real and liquidity is strong, the financial impact of strategic initiatives remains to be proven.

Announcement summary

(LSE:OBD) Oxford BioDynamics reported FY26 revenue of £1.65m, compared to £1.10m in FY25. The revenue growth was driven by approximately 4,200 EpiSwitch PSE tests sold during the year. This represents a 124% year-on-year increase in test sales. In September 2026, the company achieved a single-month record of over 500 EpiSwitch PSE tests sold. The current run-rate for test sales is more than double that of a year ago. As of 30 September 2026, cash and cash equivalents stood at £7.4m. In August 2026, Oxford BioDynamics completed an equity raise of £9.15m. An additional £0.5m was received post-period. Commercial progress during the period included the first pharma Orion agreement with Johnson & Johnson. The company also launched an Orion early-access programme. Oxford BioDynamics undertook a US reorganisation and implemented cost reductions. These measures were aimed at improving throughput and reimbursement. The company highlighted these operational and commercial milestones as key achievements for the period.

Disagree with this article?